Ghanan Bin Akhtar

Mr. Ghanan Bin Akhtar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in European Journal of Cell Biology
Verified
Journal Article
Open access
Ghanan Bin AkhtarGhanan Bin Akhtar
Ghanan Bin Akhtar
MBMarjorie Buist
Marjorie Buist
Mojgan RastegarMojgan Rastegar
Mojgan Rastegar
Eukaryotic gene expression is controlled at multiple steps that work in harmony to ensure proper maintenance of cellular morphology and function. Such regulatory mechanisms would include transcriptional gene regulation, which is in turn controlled by chromatin remodeling, distinct topologically associating domains of the chromatin structure, cis-regulatory elements such as enhancers and promoters, action of trans-acting factors, DNA methylation, RNA modifications, and post-translational modification of histones. These guiding mechanisms of gene expression play critical roles in the epigenetic setting of individual cells within the eukaryotic systems. Some epigenetic factors may play multiple functional roles in guarding the accurate gene expression program of the eukaryotic cells, especially within the central nervous system. A well-studied example of such multi-functional factors is the methyl-CpG-binding protein 2 (MeCP2), a nuclear protein that is encoded by the X-linked MECP2 gene. Here, we aim to provide an overview of eukaryotic gene regulation, the three-dimensional chromatin organization, standard techniques to study newly synthesized RNA transcripts, and the role of MeCP2 as an important transcriptional regulator in eukaryotes.

1 October 2020 in Plant Breeding
Verified
Journal Article
Closed access
PDF file
RARafiq Ahmad
Rafiq Ahmad
MHMahmood‐Ul‐ Hassan
Mahmood‐Ul‐ Hassan
Ghanan Bin AkhtarGhanan Bin Akhtar
Ghanan Bin Akhtar
SSSadia Saeed
Sadia Saeed
SKSabaz A. Khan
Sabaz A. Khan
NKNadeem Khan
Nadeem Khan

19 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
CRChris-Tiann Roberts
Chris-Tiann Roberts
ASHRAF KADAR SHAHIBASHRAF KADAR SHAHIB
ASHRAF KADAR SHAHIB
KAKhatereh Saei Arezoumand
Khatereh Saei Arezoumand
Ghanan Bin AkhtarGhanan Bin Akhtar
Ghanan Bin Akhtar
KNKazem Nejati-Koshki
Kazem Nejati-Koshki
Mojgan RastegarMojgan Rastegar
Mojgan Rastegar
Methyl CpG-binding protein 2 (MeCP2) is an epigenetic reader of DNA methylation with high abundance in the brain. While genetic mutations occur across different protein domains of MeCP2, the T158M mutation is amongst the most frequent MeCP2 mutations. MeCP2 is encoded by the MECP2/Mecp2 gene located on the X chromosome. In humans, MECP2 mutations cause Rett Syndrome, a debilitating neurodevelopmental disorder in females, with very rare cases presenting in males. Despite the generation of different transgenic mouse lines with MeCP2 mutations, the sex-dependent phenotypic and molecular impact of common MeCP2 mutations in mouse models of disease remains largely unexplored. Here, we focus on the MeCP2 T158M mutation using Mecp2tm4.1Bird/J transgenic mice (referred to as Mecp2T158M), and report that Mecp2T158M mutant mice display sex-specific molecular, behavioural, and phenotypic characteristics when compared to wild-type controls. Our data indicates sex- and brain-region-dependent impacts on the expression of MeCP2, synaptic proteins, cytoskeletal markers, and autophagy factors. Our findings demonstrate that the phenotypic and molecular characteristics of this mouse model may relate to the clinical manifestation in human patients with Rett Syndrome.

15 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KAKhatereh Saei Arezoumand
Khatereh Saei Arezoumand
Ghanan Bin AkhtarGhanan Bin Akhtar
Ghanan Bin Akhtar
ASHRAF KADAR SHAHIBASHRAF KADAR SHAHIB
ASHRAF KADAR SHAHIB
JJJessica Jarmasz
Jessica Jarmasz
CRChris-Tiann Roberts
Chris-Tiann Roberts
Mojgan RastegarMojgan Rastegar
Mojgan Rastegar
Background: Rett Syndrome (RTT) is a progressive neurodevelopmental disorder caused by MECP2 gene mutations. MeCP2 protein binding to methylated DNA is involved in normal brain development and function. T158M is a common RTT-associated mutation, where a threonine is replaced with a methionine, affecting protein function and stability. RTT has recently been identified as a neurometabolic disorder, with metformin emerging as a potential candidate drug. Metformin is a safe and accessible drug, commonly used for Type 2 diabetes. Our team previously studied the regulatory role of metformin on the expression of RTT-related genes/proteins using in vitro and in vivo approaches. However, the phenotypical and behavioral impact of metformin in transgenic mice carrying the common T158M mutation was not explored. Methods: Wild type (WT) and mutant Mecp2T158M (Mecp2tm4.1Bird) male mice were subjected to daily intraperitoneal injection of metformin for 20 days. The control mice received a daily intraperitoneal injection of the solvent. The main RTT-like phenotypical criteria were assessed daily. Behavioral tests included the open field test and elevated plus maze. Results: Behavioral tests indicated no significant effect of metformin on the anxiety levels, locomotion, and exploratory behaviors in the hemizygous male Mecp2T158M mice, despite our observation of increased anxiety levels in the WT counterparts. In hemizygous male Mecp2T158M mice, metformin treatment showed beneficial effects on RTT-like phenotypes, including breathing irregularities, gait abnormalities, hindlimb clasping, and overall total score. The positive effect of metformin was also observed on the body weight in the hemizygous male Mecp2T158M mice. Conclusions: Our findings provide evidence for potential therapeutic effects of metformin for MeCP2-associated neurological disorders.